

HEALTHY U CHIP

PRIOR AUTHORIZATION REQUEST FORM

SUNOSI

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.

| | | |
|---------------|--------------|-----------------|
| Date: | Member Name: | ID#: |
| DOB: | Gender: | Physician: |
| Office Phone: | Office Fax: | Office Contact: |

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Sunosi® (solfiamfetol)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

| Questions | Yes | No | Comments/Notes |
|--|--------------------------|--------------------------|-------------------------------------|
| EXCESSIVE SOMNOLENCE ASSOCIATED WITH NARCOLEPSY | | | |
| 1. Is the member 18 years of age or older? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 2. Does the member have a baseline ESS score of 15 or higher? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 3. Does the member have a diagnosis of narcolepsy confirmed by polysomnography and MSLT? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 4. Is Sunosi® prescribed by, or in consultation with, a sleep disorder specialist or neurologist? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 5. Has the member tried at least one agent from each of the following categories for at least 3 months each: <ul style="list-style-type: none"> • Central nervous system stimulant (e.g. methylphenidate) • Wakefulness promoting agent (e.g. modafinil) | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 6. Is the member's blood pressure adequately controlled? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 7. Will the member be monitored for psychologic disorders or exacerbations? | <input type="checkbox"/> | <input type="checkbox"/> | |
| EXCESSIVE SOMNOLENCE ASSOCIATED WITH SLEEP APNEA | | | |
| 1. Is the member 18 years of age or older? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 2. Does the member have a baseline ESS score of 15 or higher? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 3. Does the member have a diagnosis of obstructive sleep apnea confirmed by a sleep disorder specialist with either polysomnography, or OCST? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |

| | | | |
|---|--------------------------|--------------------------|-------------------------------------|
| 4. Is Sunosi® prescribed by, or in consultation with, a sleep disorder specialist or pulmonologist? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 5. Is the member being treated with non-pharmacologic primary treatment modalities (CPAP or similar)? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 6. Is the member at least 90% compliant on non-pharmacologic primary treatment modalities with at least 5 hours of use per night for at least 3 months prior to initiation of Sunosi®? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 7. Will the member continue to use CPAP therapy for at least 6 hours per night with at least 90% compliance during Sunosi® therapy? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 8. Has the member tried modafinil or armodafinil for at least 3 months while using CPAP? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 9. Is the member's blood pressure adequately controlled? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 10. Will the member be monitored for psychologic disorders or exacerbations? | <input type="checkbox"/> | <input type="checkbox"/> | |
| REAUTHORIZATION | | | |
| 1. Is the request for reauthorization of therapy? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 2. Does documentation show the member had an improvement in ESS score from baseline? <ul style="list-style-type: none"> • At least 5 point improvement for initial renewal • Maintenance of ESS score improvement for ongoing renewals | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 3. For OSA, has the member continued to use non-pharmacologic primary treatment modalities with at least 90% compliance for at least 6 hours per night? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc. | | | |
| Additional information: | | | |
| Physician Signature: | | | |

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM-CHIP-107
 Origination Date: 07/01/2024
 Reviewed/Revised Date:
 Next Review Date:
 Current Effective Date: 07/01/2024

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.